Milestone Pharmaceuticals (MIST) vs PMV Pharmaceuticals (PMVP)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 18, 2026.
Summary
PMV Pharmaceuticals (PMVP) has outperformed Milestone Pharmaceuticals (MIST) over the past year, losing 13.6% versus a loss of 63.5%. Over five years, MIST leads with a -87.3% price change compared with -95.1% for PMVP. PMV Pharmaceuticals is the larger company by market cap ($91.4 million vs $88.1 million), about 1.0 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | MIST | PMVP |
|---|---|---|
| Share price | $0.7073 | $1.21 |
| Market cap | $88.06M | $91.37M |
| 1-day change | -10.98% | -6.20% |
| YTD return | -64.99% | -3.20% |
| 1-year return | -63.54% | -13.57% |
| 5-year return | -87.27% | -95.07% |
| EPS (TTM) | $-0.68 | $-1.42 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Net income (latest FY) | $-63.06M | $-77.74M |
| 52-week high | $3.06 | $1.91 |
| 52-week low | $0.704 | $1.02 |
| Distance from 52-week high | -76.89% | -36.65% |
| Analyst consensus | none | none |
| Avg. price target upside | +728.50% | +247.11% |
| Average volume | 1.42M | 662.27K |
| Shares outstanding | 124.50M | 75.51M |
| Employees | 38 | 54 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- PMVP has outperformed MIST by 50.0 percentage points over the past year.
About Milestone Pharmaceuticals
MIST stock →Milestone Pharmaceuticals Inc., a biopharmaceutical company, focuses on the development and commercialization of cardiovascular medicines in the United States and Canada. It offers CARDAMYST (etripamil) nasal spray, a prescription medication for the conversion of acute symptomatic episodes of paroxysmal supraventricular tachycardia (PSVT) to sinus rhythm in adults.
Health Care · Biotechnology: Pharmaceutical Preparations · 38 employees
About PMV Pharmaceuticals
PMVP stock →PMV Pharmaceuticals, Inc., a precision oncology company, engages in the discovery and development of small molecule therapies targeting p53 mutations and other p53-related cancers in the United States. It develops rezatapopt, a selective structural corrector of p53 Y220C mutations in Phase 2 clinical trials for tumor agnostic diseases.
Health Care · Biotechnology: Pharmaceutical Preparations · 54 employees
MIST vs PMVP FAQ
Which is bigger, Milestone Pharmaceuticals or PMV Pharmaceuticals?
PMV Pharmaceuticals (PMVP) is larger, with a market capitalization of $91.37M compared with $88.06M for Milestone Pharmaceuticals (MIST).
Which stock has performed better over the past year, MIST or PMVP?
PMVP returned -13.57% over the past 12 months, compared with -63.54% for MIST (price return, excluding dividends). Past performance does not predict future results.
Are Milestone Pharmaceuticals and PMV Pharmaceuticals in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.